Prokidney
ProKidney is a biotechnology company developing cell therapy products like REACT to transform the treatment of Chronic Kidney Disease (CKD), focusing on delaying kidney failure and reducing the need for dialysis.
Services
Prokidney develops cell therapy candidates aimed at transforming the treatment landscape for Chronic Kidney Disease (CKD). The company's primary focus is on delaying the progression to kidney failure and the need for dialysis through cellular therapy. Prokidney's approach includes the utilization of their cell therapy product, REACT, which may halt the progression of CKD and promote substantial improvement in kidney function. The company provides personalized treatment options composed of cells prepared from a patient’s own kidney, thus eliminating the need for immunosuppressive therapies.
Products
Prokidney offers a cell therapy product known as REACT. This product is designed to stop the progression of Chronic Kidney Disease (CKD) and promote meaningful improvement in kidney function. REACT is currently under evaluation through multiple clinical trials, including a Phase 3 development program and several Phase 2 trials involving subjects with moderate to severe diabetic kidney disease. Additionally, Prokidney is conducting a Phase 1 clinical trial for REACT in subjects with congenital anomalies of the kidney and urinary tract (CAKUT). REACT has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
Clinical Trials
Prokidney is actively involved in a range of clinical trials to evaluate the effectiveness of its cell therapy product, REACT. The company is conducting a Phase 3 development program and several Phase 2 clinical trials targeting subjects with moderate to severe diabetic kidney disease. Additionally, Prokidney is running a Phase 1 clinical trial focused on subjects with congenital anomalies of the kidney and urinary tract (CAKUT). These trials aim to demonstrate REACT's potential to stop the progression of Chronic Kidney Disease and promote improvement in kidney function.
Headquarters
Prokidney is headquartered in Winston-Salem, North Carolina, USA. The company operates a Good Manufacturing Practice (GMP) facility that includes several clean rooms, ensuring high standards of quality in the manufacturing of cellular therapy products. Prokidney employs patented technology in manufacturing automation, supply chain management, and the medical delivery of their cellular therapy products.
Chronic Kidney Disease Statistics
Prokidney estimates that approximately 38-39 million adults in the United States suffer from Chronic Kidney Disease (CKD). Among these individuals, about 17-18 million patients are at stage 3 or 4 of CKD. The company's focus on cellular therapy aims to address the needs of this significant population by providing innovative treatment options that delay kidney failure and the need for dialysis.
